CLINICAL SERIES - Tysabri & MS Care: Safety, Standards, and Clinical Insight

Clinical Edge: REMS Program: What is it & Why Does it Matter (March 17)

This session will provide professionals with an overview of the REMS program and how it applies to patients receiving Tysabri.

1. Describe the natalizumab REMS program and its purpose.
2. Discuss the role of the REMS program in promoting patient safety for high-risk medications like natalizumab.
3. Explain key responsibilities of health care professionals within the REMS program.

Clinical Connect: Multiple Sclerosis (March 18)

This session will provide professionals with an overview of Multiple Sclerosis and the IV medications prescribed for treatment.

1. Describe the pathophysiology and clinical presentation of Multiple Sclerosis.
2. Discuss the role and mechanisms of IV therapy indicated to treat Multiple Sclerosis.
3. Explain key clinical considerations and patient education points for infusion-based MS treatments.

Clinical Edge: Post Monitoring ADR Reporting (March 19)

This session will provide professionals with an overview of the key indicators for post monitoring and how to report adverse drug reactions related to patients receiving Tysabri.

1. Describe the purpose and process of post-infusion monitoring for patients on Tysabri.
2. Discuss common and serious adverse drug reactions associated with Tysabri.
3. Explain the appropriate steps for documenting and reporting ADRs per protocol and REMS requirements.

REGISTER